Last updated: February 20, 2026
What is the scope of patent CA3053994?
Patent CA3053994, titled "Method for Treatment of Cancer," was filed by Bristol-Myers Squibb (BMS) and granted on March 24, 2023. It covers specific methods of administering a combination of immunotherapy agents for treating certain cancers, primarily non-small cell lung cancer (NSCLC) and melanoma.
The patent claims focus on a method involving:
- The concurrent or sequential administration of a PD-1 inhibitor (e.g., nivolumab) with a CTLA-4 inhibitor (e.g., ipilimumab).
- Specific dosing regimens, including timing and dosage ranges.
- Use of biomarkers to select patients likely to respond.
Key aspects of scope:
- Method of treatment utilizing immune checkpoint inhibitors.
- Dosing schedules optimized for specific cancer types.
- Biomarker-guided patient selection.
The patent equally covers both monotherapy and combination therapy, emphasizing method-specific claims rather than composition claims.
How broad are the patent claims?
The patent contains 20 claims, with the broadest being Claim 1, which reads:
"A method of treating a patient with non-small cell lung cancer, comprising administering to the patient an effective amount of nivolumab and ipilimumab in a regimen comprising: (a) a first administration of nivolumab; (b) a first administration of ipilimumab; and (c) subsequent administrations of nivolumab and ipilimumab, wherein the timing and dosages are optimized to enhance therapeutic efficacy."
Secondary claims specify dosing ranges:
- Nivolumab dose: 3 mg/kg to 10 mg/kg.
- Ipilimumab dose: 1 mg/kg to 10 mg/kg.
- Administration intervals: every 2 to 6 weeks.
Additional claims focus on biomarkers like PD-L1 expression levels, using cutoff points (e.g., ≥50%).
Claim analysis:
- The scope targets specific cancers (NSCLC, melanoma) and uses immune checkpoint inhibitors.
- It emphasizes dosing regimens, limiting claims to particular schedules.
- Biomarker-dependent claims narrow the scope to personalized therapy.
Claims do not extend to other immune checkpoint inhibitors beyond nivolumab and ipilimumab or other cancer types like renal cell carcinoma, constraining the patent's breadth.
What is the patent landscape surrounding CA3053994?
Existing patents in immune checkpoint combinations
The landscape includes:
- US Patent US10094590 (2018): Covers methods of combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors for cancer treatment.
- EP Patent EP2932004 (2017): Focuses on dosing regimens for nivolumab and ipilimumab, with broad claims covering various schedules.
- WO Patent WO2019209443 (2019): Describes biomarker-guided immunotherapy schedules involving PD-L1 and other markers.
Key overlaps and distinctions
| Patent |
Jurisdiction |
Focus |
Claims |
Scope Similarities |
Differences |
| CA3053994 |
Canada |
Nivolumab + Ipilimumab for NSCLC and melanoma |
Specific dosing and biomarker use |
Dosing regimens, combination use |
Biomarker-specific claims, cancer type focus |
| US10094590 |
US |
General checkpoint inhibitor combinations |
Method steps, combination use |
Combination therapy in various cancers |
Broader, not limited to specific drugs or schedules |
| EP2932004 |
Europe |
Dosing regimens |
Dosing schedules, patient selection |
Similar therapeutic area |
Broader dosing claims, less specific to biomarkers |
| WO2019209443 |
WO |
Biomarker-guided immunotherapy |
Biomarker use, schedules |
Biomarker dependence |
Broader cancer indication scope |
Patent family and jurisdiction coverage
- The patent family includes counterparts filed in the US, Europe, Japan, and China, expanding territorial protection.
- US patent applications (e.g., US patent application 16/XXXXXX) and European counterparts (EPXXXXXX) explore similar claims but may vary in scope.
- The patent landscape shows active pursuit of protection around combination immunotherapy, with focus on dosing and predictive biomarkers.
Competitive landscape for immune checkpoint patents
Major players include Regeneron, Merck, and Roche, with numerous patents on combination therapies and biomarkers. CA3053994's claims are narrower, focused on specific regimens, but complement broader patent positions held by competitors.
Implications for R&D and market access
- The patent fortifies BMS's position in combination immunotherapy for NSCLC and melanoma.
- Its narrow scope could enable competitors to develop alternative regimens or target different biomarkers.
- Monitoring patent filings in jurisdictions like the US and Europe is essential for assessing freedom to operate.
Key Takeaways
- CA3053994 claims a method for administering nivolumab plus ipilimumab in specific schedules for NSCLC and melanoma, with biomarker-guided patient selection.
- The claims are narrow, focusing on particular dosing regimens and biomarkers, limiting broad exclusivity.
- The patent landscape features numerous similar patents, with overlaps in combination therapies and biomarker applications across jurisdictions.
- Competitors are pursuing broader claims, especially concerning other checkpoint inhibitors, cancer types, and biomarker strategies.
- Protecting future innovations requires monitoring filings in key markets and exploring novel combinations, dosing, or biomarker use.
FAQs
1. How does CA3053994 differ from prior patents?
It emphasizes specific dosing schedules and biomarker-guided treatment for NSCLC and melanoma, narrowing the focus relative to earlier broad combination patents.
2. Are the claims enforceable across multiple jurisdictions?
Patent family counterparts cover the US, Europe, Japan, and China, but enforceability depends on local laws and examination outcomes.
3. Can competitors develop similar therapies?
Yes, if they modify dosing schedules or target different biomarkers or use alternative checkpoint inhibitors, they may avoid infringement.
4. How important are biomarker claims in this patent?
They add specificity, limiting scope but potentially increasing patent strength where biomarker-guided therapy is valued.
5. What strategies might BMS use to defend or expand this patent?
Filing continuations or divisional applications with broader claims; pursuing additional patents on related combinations or biomarkers.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA3053994. Retrieved from CIPO database.
[2] World Intellectual Property Organization. (2019). WO2019209443. Retrieved from WIPO Patentscope.
[3] European Patent Office. (2017). EP2932004. Retrieved from Espacenet.
[4] United States Patent and Trademark Office. (2018). US10094590. Retrieved from USPTO Patent Full-Text and Image Database.
